254 related articles for article (PubMed ID: 31121213)
1. PAK4 regulates stemness and progression in endocrine resistant ER-positive metastatic breast cancer.
Santiago-Gómez A; Kedward T; Simões BM; Dragoni I; NicAmhlaoibh R; Trivier E; Sabin V; Gee JM; Sims AH; Howell SJ; Clarke RB
Cancer Lett; 2019 Aug; 458():66-75. PubMed ID: 31121213
[TBL] [Abstract][Full Text] [Related]
2. Anti-estrogen Resistance in Human Breast Tumors Is Driven by JAG1-NOTCH4-Dependent Cancer Stem Cell Activity.
Simões BM; O'Brien CS; Eyre R; Silva A; Yu L; Sarmiento-Castro A; Alférez DG; Spence K; Santiago-Gómez A; Chemi F; Acar A; Gandhi A; Howell A; Brennan K; Rydén L; Catalano S; Andó S; Gee J; Ucar A; Sims AH; Marangoni E; Farnie G; Landberg G; Howell SJ; Clarke RB
Cell Rep; 2015 Sep; 12(12):1968-77. PubMed ID: 26387946
[TBL] [Abstract][Full Text] [Related]
3. Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro.
Jordan NJ; Dutkowski CM; Barrow D; Mottram HJ; Hutcheson IR; Nicholson RI; Guichard SM; Gee JM
Breast Cancer Res; 2014 Jan; 16(1):R12. PubMed ID: 24457069
[TBL] [Abstract][Full Text] [Related]
4. FKBPL and its peptide derivatives inhibit endocrine therapy resistant cancer stem cells and breast cancer metastasis by downregulating DLL4 and Notch4.
McClements L; Annett S; Yakkundi A; O'Rourke M; Valentine A; Moustafa N; Alqudah A; Simões BM; Furlong F; Short A; McIntosh SA; McCarthy HO; Clarke RB; Robson T
BMC Cancer; 2019 Apr; 19(1):351. PubMed ID: 30975104
[TBL] [Abstract][Full Text] [Related]
5. Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells.
Basak P; Chatterjee S; Bhat V; Su A; Jin H; Lee-Wing V; Liu Q; Hu P; Murphy LC; Raouf A
Cell Physiol Biochem; 2018; 51(4):1518-1532. PubMed ID: 30497079
[TBL] [Abstract][Full Text] [Related]
6. p21-activated kinase group II small compound inhibitor GNE-2861 perturbs estrogen receptor alpha signaling and restores tamoxifen-sensitivity in breast cancer cells.
Zhuang T; Zhu J; Li Z; Lorent J; Zhao C; Dahlman-Wright K; Strömblad S
Oncotarget; 2015 Dec; 6(41):43853-68. PubMed ID: 26554417
[TBL] [Abstract][Full Text] [Related]
7. Self-renewal of CD133(hi) cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancer.
Sansone P; Ceccarelli C; Berishaj M; Chang Q; Rajasekhar VK; Perna F; Bowman RL; Vidone M; Daly L; Nnoli J; Santini D; Taffurelli M; Shih NN; Feldman M; Mao JJ; Colameco C; Chen J; DeMichele A; Fabbri N; Healey JH; Cricca M; Gasparre G; Lyden D; Bonafé M; Bromberg J
Nat Commun; 2016 Feb; 7():10442. PubMed ID: 26858125
[TBL] [Abstract][Full Text] [Related]
8. IL-33 facilitates endocrine resistance of breast cancer by inducing cancer stem cell properties.
Hu H; Sun J; Wang C; Bu X; Liu X; Mao Y; Wang H
Biochem Biophys Res Commun; 2017 Apr; 485(3):643-650. PubMed ID: 28216163
[TBL] [Abstract][Full Text] [Related]
9. SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer.
Alves CL; Elias D; Lyng MB; Bak M; Ditzel HJ
Breast Cancer Res; 2018 Jun; 20(1):60. PubMed ID: 29921289
[TBL] [Abstract][Full Text] [Related]
10. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.
Fu X; Creighton CJ; Biswal NC; Kumar V; Shea M; Herrera S; Contreras A; Gutierrez C; Wang T; Nanda S; Giuliano M; Morrison G; Nardone A; Karlin KL; Westbrook TF; Heiser LM; Anur P; Spellman P; Guichard SM; Smith PD; Davies BR; Klinowska T; Lee AV; Mills GB; Rimawi MF; Hilsenbeck SG; Gray JW; Joshi A; Osborne CK; Schiff R
Breast Cancer Res; 2014 Sep; 16(5):430. PubMed ID: 25212826
[TBL] [Abstract][Full Text] [Related]
11. Cancer stem-like properties of hormonal therapy-resistant breast cancer cells.
Uchiumi K; Tsuboi K; Sato N; Ito T; Hirakawa H; Niwa T; Yamaguchi Y; Hayashi SI
Breast Cancer; 2019 Jul; 26(4):459-470. PubMed ID: 30610551
[TBL] [Abstract][Full Text] [Related]
12. The forkhead transcription factor FOXM1 promotes endocrine resistance and invasiveness in estrogen receptor-positive breast cancer by expansion of stem-like cancer cells.
Bergamaschi A; Madak-Erdogan Z; Kim YJ; Choi YL; Lu H; Katzenellenbogen BS
Breast Cancer Res; 2014 Sep; 16(5):436. PubMed ID: 25213081
[TBL] [Abstract][Full Text] [Related]
13. Nitric oxide-targeted therapy inhibits stemness and increases the efficacy of tamoxifen in estrogen receptor-positive breast cancer cells.
López-Sánchez LM; Mena R; Guil-Luna S; Mantrana A; Peñarando J; Toledano-Fonseca M; Conde F; De la Haba-Rodríguez JR; Aranda E; Rodríguez-Ariza A
Lab Invest; 2021 Mar; 101(3):292-303. PubMed ID: 33262438
[TBL] [Abstract][Full Text] [Related]
14. Acquired Resistance of ER-Positive Breast Cancer to Endocrine Treatment Confers an Adaptive Sensitivity to TRAIL through Posttranslational Downregulation of c-FLIP.
Piggott L; Silva A; Robinson T; Santiago-Gómez A; Simões BM; Becker M; Fichtner I; Andera L; Young P; Morris C; Barrett-Lee P; Alchami F; Piva M; Vivanco MD; Clarke RB; Gee J; Clarkson R
Clin Cancer Res; 2018 May; 24(10):2452-2463. PubMed ID: 29363524
[No Abstract] [Full Text] [Related]
15. Targeting STAT3 signaling using stabilised sulforaphane (SFX-01) inhibits endocrine resistant stem-like cells in ER-positive breast cancer.
Simões BM; Santiago-Gómez A; Chiodo C; Moreira T; Conole D; Lovell S; Alferez D; Eyre R; Spence K; Sarmiento-Castro A; Kohler B; Morisset L; Lanzino M; Andò S; Marangoni E; Sims AH; Tate EW; Howell SJ; Clarke RB
Oncogene; 2020 Jun; 39(25):4896-4908. PubMed ID: 32472077
[TBL] [Abstract][Full Text] [Related]
16. Biological effects of fulvestrant on estrogen receptor positive human breast cancer: short, medium and long-term effects based on sequential biopsies.
Agrawal A; Robertson JF; Cheung KL; Gutteridge E; Ellis IO; Nicholson RI; Gee JM
Int J Cancer; 2016 Jan; 138(1):146-59. PubMed ID: 26178788
[TBL] [Abstract][Full Text] [Related]
17. Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer.
Kaminska K; Akrap N; Staaf J; Alves CL; Ehinger A; Ebbesson A; Hedenfalk I; Beumers L; Veerla S; Harbst K; Ehmsen S; Borgquist S; Borg Å; Pérez-Fidalgo A; Ditzel HJ; Bosch A; Honeth G
Breast Cancer Res; 2021 Feb; 23(1):26. PubMed ID: 33602273
[TBL] [Abstract][Full Text] [Related]
18. HNRNPA2B1 regulates tamoxifen- and fulvestrant-sensitivity and hallmarks of endocrine resistance in breast cancer cells.
Petri BJ; Piell KM; South Whitt GC; Wilt AE; Poulton CC; Lehman NL; Clem BF; Nystoriak MA; Wysoczynski M; Klinge CM
Cancer Lett; 2021 Oct; 518():152-168. PubMed ID: 34273466
[TBL] [Abstract][Full Text] [Related]
19. Fulvestrant-Mediated Attenuation of the Innate Immune Response Decreases ER
Abrahamsson A; Rodriguez GV; Dabrosin C
Cancer Res; 2020 Oct; 80(20):4487-4499. PubMed ID: 32855207
[TBL] [Abstract][Full Text] [Related]
20. Role of RBP2-Induced ER and IGF1R-ErbB Signaling in Tamoxifen Resistance in Breast Cancer.
Choi HJ; Joo HS; Won HY; Min KW; Kim HY; Son T; Oh YH; Lee JY; Kong G
J Natl Cancer Inst; 2018 Apr; 110(4):. PubMed ID: 29028222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
